Zydus receives final approval from USFDA for Erlotinib Tablets

Zydus receives final approval from USFDA for Erlotinib Tablets Ahmedabad, April 17, 2020 Zydus Cadila has received final approval from the USFDA to market Erlotinib Tablets (US RLD: Tarceva® Tablets), in the strengths of 25 mg, 100 mg, and 150 mg. Erlotinib is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. It is also used to treat non-small cell lung cancer or pancreatic cancer that has spread to other parts of the body (metastatic). Erlotinib is usually given after other cancer medicines have been tried without success. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, in Ahmedabad. The group now has 288 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗